Identifying genomic drivers and targeting those specific alterations with therapy are a critical aspect of personalized medicine. Traditionally, this has been done through tissue-based mutation testing, but the landscape is evolving rapidly towards less invasive blood-based approaches. Tracking tumor-associated genetic aberrations in the blood can be used to quickly determine whether targeted therapies are a treatment option; assessing the response to therapy, presence of residual disease, recurrence, and detecting the emergence of therapy-resistant cancer cells more quickly than conventional tissue-based methods.
We leverage Droplet Digital PCR (ddPCR™) to detect gene mutations in plasma cell-free DNA and RNA, tissue, cells, and other specimen types. ddPCR is highly sensitive, cost-effective, quantitative and has a fast turnaround time suited for monitoring a range genetic changes in tissue and blood. Through the design of custom assays or the use of our on-market GeneStrat® test, we offer the ability to retrospectively analyze clinical trial samples, prospectively enroll clinical trial patients, and coordinate commercialization.
Next Generation Sequencing (NGS) is a high throughput, massively parallel sequencing technique that can generate large amounts of clinically relevant data. We offer a broad range of blood and tissue-based NGS testing solutions, including comprehensive cell-free nucleic acid assays, tumor mutation burden testing, and immune response analyses.